Loading clinical trials...
Loading clinical trials...
Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Anti-PD-L1) in Combination With Cabozantinib in Patients With Recurrent Glioblastoma (rGBM)
Conditions
Interventions
Atezolizumab
Cabozantinib
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
September 23, 2022
Primary Completion Date
December 31, 2027
Completion Date
December 31, 2027
Last Updated
December 19, 2025
NCT05789394
NCT06860594
NCT06344130
NCT07209241
NCT06910306
NCT06552260
Lead Sponsor
M.D. Anderson Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions